XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 13:20 PDT] XTL Biopharmaceuticals Ltd (NASDAQ:XTLB), Up By 100% ($1.22) From $1.22 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/25/2025 13:20 PDT] XTL Biopharmaceuticals Ltd (NASDAQ:XTLB), Up By 100% ($1.13) From $1.13 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/25/2025 13:20 PDT] XTL Biopharmaceuticals Ltd (NASDAQ:XTLB), Up By 100% ($1.13) From $1.13 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/24/2025 07:34 PDT] XTLB Expected to Trade Up After Bullish Patterns Develop
• [04/21/2025 07:09 PDT] XTLB Expected to Trade Up After Bullish Patterns Develop
• [04/17/2025 07:03 PDT] XTLB Expected to Trade Up After Bullish Patterns Develop
• [03/26/2025 07:13 PDT] XTLB Expected to Trade Down After Bearish Patterns Develop